UNSPSC 51112510: Ifosfamide

This classification denotes a nitrogen mustard compound with the molecular formula C7H15Cl2N2O2P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UM20QQM95Y, chemically known as 1,3,2-oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide but more generally known as ifosfamide, which bears US NIH Compound Identifier 3690. European Medicines Agency schedules Ifosfamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08125MIG.

UNSPSC 51112510 Ifosfamide, a Commodity code, nominally covers procurement of the chemotherapy drug ifosfamide, though recent state and local solicitation activity under this code is minimal and tangential. The Texas Health and Human Services Commission posted a Request for Information (RFI) in early April 2026 seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, which addresses pharmaceutical procurement strategy and pharmacy benefit management rather than purchase of a specific drug product. The RFI solicits information on vendors' capacity to establish direct contracts between state pharmacy programs and manufacturers, negotiate net pricing models outside traditional pharmacy benefit manager and group purchasing organization channels, and implement outcomes-based agreements — a market-intelligence exercise designed to inform future formal solicitations rather than a direct procurement of ifosfamide or similar chemotherapy agents.

State and local procurement activity under this Commodity code does not currently reflect routine or active buying of ifosfamide itself. The single recent opportunity documented is a preliminary RFI from a state health agency exploring structural changes to how the state manages pharmaceutical procurement broadly, not a solicitation for chemotherapy inventory or patient-care delivery. The Texas HHS Commission's initiative targets pharmacy benefit program reform and direct manufacturer relationships; the RFI carries no award value, budget, or timeline binding the state to specific drug purchases. Geographic activity is limited to Texas as of mid-2026, and no repeat issuing bodies or established market pattern supports pursuit under this code at present.